Staff Profile: Sharie J. Haugabook

Sharie J. Haugabook, Ph.D.

Senior Project Manager/Drug Development Team Lead

Division of Pre-Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

Email Sharie J. Haugabook

Biography

Sharie Haugabook is a senior project manager and drug development team lead of the Therapeutics for Rare and Neglected Diseases (TRND) program in the Therapeutics Development Branch of NCATS’ Division of Pre-Clinical Innovation, where she leads and manages early therapeutic development projects in the TRND portfolio.

Prior to joining NCATS in August 2014, she spent seven and a half years at Merck & Company. She supported and led early drug discovery programs in neuroscience and pharmacology, initially as a senior research biochemist and then as an associate principal scientist.

Haugabook received her Ph.D. in biomedical sciences/pharmacology from the Mayo Clinic College of Medicine at the Mayo Graduate School in Rochester, Minnesota. As a postdoctoral fellow, she earned an M.S. in clinical research as an Institute for Research Minority Training on Mental Health and Aging (IRMMA) Fellow at the Medical University of South Carolina. Haugabook earned her B.S. in chemistry with minors in biology and mathematics from the University of Miami.

Research Topics

Haugabook’s current research interest is early drug development efforts for rare and neglected diseases.

Selected Publications

  1. Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency.
  2. A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.
  3. Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.
  4. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta).
  5. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.